Sps and Vitamin d drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Sps (sodium polystyrene sulfonate) and Vitamin d (ergocalciferol). Common drug interactions include anhedonia among females and anhedonia among males.

The phase IV clinical study analyzes what interactions people have when they take Sps and Vitamin d. It is created by eHealthMe based on reports of 15 people who take the same drugs from the FDA, and is updated regularly.

What is Sps?

Sps has active ingredients of sodium polystyrene sulfonate. eHealthMe is studying from 105 Sps users. Check the latest studies of Sps.

What is Vitamin d?

Vitamin d has active ingredients of ergocalciferol. It is often used in low vitamin d. eHealthMe is studying from 294,095 Vitamin d users. Check the latest studies of Vitamin d.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

15 people who take Sps and Vitamin d together, and have interactions are studied.

What are the common drug interactions of Sps and Vitamin D, by gender? *:

female:

Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
Chronic kidney disease
Depression
Diarrhoea
Emotional distress
Fanconi syndrome acquired (self developed genetic disease of kidney damage due to defective transport system)
Muscle spasms (muscle contraction)
Nephrogenic anaemia (anaemia due to kidney disease)
Osteopenia (a condition where bone mineral density is lower than normal)

male:

Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
Tooth loss
Blood creatinine increased
Emotional distress
Osteopenia (a condition where bone mineral density is lower than normal)
Pain
Renal disorder (kidney disease)
Renal failure (kidney dysfunction)
Blood glucose increased

What are the common drug interactions of Sps and Vitamin D, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Hospitalisation

30-39:

n/a

40-49:

Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
Chronic kidney disease
Depression
Diarrhoea
Emotional distress
Fanconi syndrome acquired (self developed genetic disease of kidney damage due to defective transport system)
Muscle spasms (muscle contraction)
Nephrogenic anaemia (anaemia due to kidney disease)
Osteopenia (a condition where bone mineral density is lower than normal)

50-59:

n/a

60+:

Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
Anticoagulation drug level below therapeutic
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Blood glucose increased
Breast cancer female
Cardiac disorder
Dysgeusia (disorder of the sense of taste)
Fatigue (feeling of tiredness)
Malignant neoplasm progression (cancer tumour came back)

What are the existing conditions these people have? *

Hyperkalemia (damage to or disease of the kidney): 5 people, 33.33%
Hiv Infection: 5 people, 33.33%
High Blood Pressure: 3 people, 20.00%
Hepatitis C: 3 people, 20.00%
Diabetes: 3 people, 20.00%
Pain: 1 person, 6.67%
Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 1 person, 6.67%
Multiple Myeloma (cancer of the plasma cells): 1 person, 6.67%
Breast Cancer Female: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Sps and Vitamin d?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously